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Introduction
Apremilast  [CC-10004;  (+)-N-[2-[(1S)-1-(3-ethoxy-4-
methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo- 
2,3-dihydro-1H-isoindol-4-yl]acetamide] (Figure 1) is an 
oral agent that inhibits the activity of phosphodiesterase 
type 4 (PDE4) and the production of multiple pro-inflam-
matory  cytokines  and  chemokines  in  vitro,  including 
tumour necrosis factor (TNF)-α, interleukin (IL)-8, IL-12, 
IL-23, CXCL9, CXCL10 and interferon-γ (Man et al. 2009; 
Schafer et al. 2010). Apremilast has demonstrated anti-
inflammatory effects in vitro and has shown efficacy in 
a pre-clinical mouse model for psoriasis (Schafer et al. 
2010). Additionally, apremilast has shown clinical efficacy 
in subjects with moderate-to-severe psoriasis (Papp et al. 
2008). Apremilast is also under clinical development for 
the treatment of other inflammatory autoimmune disor-
ders that involve elevated cytokine levels such as psori-
atic arthritis and Behçet disease.
The  pharmacokinetics  of  apremilast  in  patients 
with  severe  plaque-type  psoriasis  following  multiple 
daily doses showed rapid absorption (Tmax = 2 h) and a 
moderately  long  half-life  (8.2 h)  (Gottlieb  et  al.  2008). 
Co-administration  of  apremilast  with  ketoconazole 
resulted in a 36% increase in apremilast AUC (Wu et al. 
2006),  not  only  indicating  that  CYP3A4/5  metabolism 
plays an important role in apremilast clearance but also 
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suggesting  that  other  clearance  pathways  are  present. 
This study was performed to evaluate the pharmacokinet-
ics, metabolic disposition and mass balance of a single 
oral suspension dose (20 mg, 100 μCi) of [14C]apremilast 
to healthy male subjects.
Materials and methods
Standards and reagents
[14C]Apremilast  (Figure  1)  was  prepared  by  Girindus 
America, Inc (Bergisch Gladbach, Germany). The spe-
cific activity, radiochemical purity and chemical purity 
of the material were 5 μCi/mg, >98% and >98%, respec-
tively. Reference standard for apremilast (99.1% chemi-
cal purity) was synthesized by Evotec (Oxfordshire, UK). 
CC-10047  (M5,  O-desethyl  apremilast),  CC-10055 
(M7,  N-deacetyl  apremilast),  CC-15091  (M1/M2, 
phthalimide  ring  hydrolysis  products  of  apremilast), 
CC-16085  (M3,  O-desmethyl  apremilast),  CC-16166 
(M12, O-desmethyl apremilast glucuronide), CC-16401 
(M17, acetamide hydroxy metabolite), CC-16557 (M16, 
acetamide hydroxyl glucuronide) and CC-16793 (M14, 
O-desmethyl, N-deacetyl apremilast glucuronide) were 
synthesized  by  the  Medicinal  Chemistry  and  Process 
Chemistry groups at Celgene (Summit, NJ). (3S-cis)-(+)-
Tetrahydro-3,7adiphenylpyrrolo[2,  1-b]  oxazol-5(6H)-
one  and  β-glucuronidase  (S8162)  were  obtained  from 
SigmaAldrich (Milwaukee, WI). All other reagents and 
chemicals were obtained from commercial sources.
Study design and dose administration
This  was  an  open-label,  inpatient,  single-dose  study 
conducted  with  six  non-smoking  healthy  male  volun-
teers,  aged  between  19  and  55  years,  with  body  mass 
index between 19 and 29 kg/m2. Before initiation of the 
study, the protocol and consent form were reviewed and 
approved  by  the  institutional  review  board.  All  study 
participants gave written informed consent before the 
screening process was initiated. This study was conducted 
in full accordance with the Declaration of Helsinki and 
Good Clinical (GCP) as required by and described in 21 
Code of Federal Regulations.
Each subject was administered a single oral suspen-
sion  of  20 mg  (100  μCi)  of  [14C]apremilast  in  distilled 
water  (240 mL  total  volume).  Subjects  were  fasted  for 
8 h prior to and 4 h following dose administration. The 
residual radioactivity in the dosing vials was determined 
and accounted for approximately 0.3% of the total radio-
activity. Dose administration, sample collection, sample 
processing  and  determination  of  total  radioactivity 
were conducted at MDS Pharma Services (Lincoln, NE). 
Determination of apremilast in plasma, metabolite pro-
filing and metabolite characterization were performed at 
XenoBiotic Laboratories, Inc. (Plainsboro, NJ).
Sample collection
Urine was collected pre-dose, 0−4, 4−8, 8−12, 12−24 and 
every 24 h thereafter up to 216 h (9 days) following dose 
administration and was stabilized with one volume of 
pH 1.5 Sorensen’s citrate buffer (25-mM sodium citrate 
buffer adjusted to pH 1.5). Individual faecal samples were 
collected pre-dose and for up to 9 days following dose 
administration, and homogenized using approximately 
three volumes by weight of pH 1.5 Sorensen’s citrate buf-
fer. Blood (two 5-mL samples for plasma radioactivity 
counting, a 3-mL sample for whole blood radioactivity 
counting, a 2-mL sample for apremilast analysis and a 
10-mL  sample  for  metabolite  profiling)  was  collected 
into heparinized tubes at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 
4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144 and 168 h fol-
lowing  dose  administration.  Blood  samples  collected 
for radioactivity counting were stored at or below −20°C 
until analysed. Plasma was harvested by centrifugation 
from all other blood samples. The plasma samples for 
apremilast analysis and metabolite profiling were mixed 
with an equal volume of pH 1.5 Sorensen’s citrate buffer 
containing 20-μM amastatin. All urine, faecal homoge-
nates and plasma samples were stored at or below −20°C 
until analysed.
Radioanalysis
All  radioactivity  determinations  were  performed  using 
a  Tri-Carb  model  1600TR  liquid  scintillation  counter 
(PerkinElmer, Wellesley, MA). For plasma and urine analy-
sis, duplicate samples of a known volume were mixed with 
Ultima Gold XR scintillation cocktail and directly analysed 
by liquid scintillation counting. For faecal homogenate 
and  blood  samples,  duplicate  aliquots  were  weighed, 
allowed  to  dry  and  combusted  using  a  PerkinElmer 
model 307 sample oxidizer. The resultant [14C]CO2 was 
trapped in Carbosorb (PerkinElmer) in combination with 
Permafluor and assayed by liquid scintillation counting. 
For all matrices, an appropriate quench curve was used to 
convert cpm values to dpm values. Any sample that was 
less than two times the background dpm was assigned a 
value of zero. Using these criteria, the lower limit of quan-
tification in plasma, blood, urine and faeces were 2.07 ng 
[14C]apremilast equivalent/mL (ngEq/mL), 2.61 ngEq/g, 
1.89 ngEq/mL and 2.52 ngEq/g, respectively.
Measurement of apremilast in plasma
Plasma  concentrations  of  apremilast  were  determined 
using  a  Chiral  liquid  chromatography  with  tandem 
mass  spectrometry  (LC/MS/MS)    assay  validated  for 
concentrations  between  1.00  and  1000 ng/mL,  with 
Figure 1.  Structure of apremilast, with the site of the  14C label 
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quality  control  (QC)  samples  prepared  at  3.00,  50.0 
and 750 ng/mL. Apremilast and (3S-cis)-(+)-tetrahydro-
3,7a-diphenylpyrrolo[2, 1-b] oxazol-5(6H)-one (internal   
standard;  IS)  were  extracted  from  50  μL  of  plasma 
(stabilized  with  50-μL  Sorenson’s  citrate  buffer)  using 
liquid−liquid extraction with methyl tertiary butyl ether. 
The aqueous layer was frozen and the solvent layer was 
transferred to a new tube. The solvent was evaporated, the 
samples were reconstituted and injected for LC/MS/MS 
analysis using a Chiral AGP (150 × 4.0 mm, 5 μm; Chrom 
Tech, Inc., Apple Valley, MN) analytical column. Positive 
ions were measured in the multiple reaction monitor-
ing (MRM) mode using a Sciex API-4000 tandem mass 
spectrometer  equipped  with  a  Turbo  IonSpray  source 
with  precursor→product  ion  pairs  of  461.0→177.9  for 
apremilast and 280.1→160.3 for IS. For the QC samples, 
the accuracy ranged from 87.5% to 106.7%.
Metabolite profiling by high-performance liquid 
chromatography (HPLC)
Individual  plasma  samples  collected  from  all  subjects 
at 0.5, 1, 2.5, 8, 24, 36 and 48 h post-dose were analysed 
for metabolite profiling. A pooled sample (equal volume 
from 0.5, 1, 2.5, 8 and 24 h) from subject 1 was also used for 
metabolite profiling. Three volumes of acetonitrile were 
added to each sample, followed by mixing and centrifu-
gation. The supernatant was removed and the pellet was 
washed twice with acetonitrile. The combined superna-
tants were evaporated to dryness under a stream of nitro-
gen. The residues were re-suspended in acetonitrile:1% 
formic acid in water (1:1), assayed for extraction recovery 
and analysed for metabolite profiling.
For each subject, urine samples were pooled using an 
equal percentage by volume of the 0−4, 4−8, 8−12 and 
12−24-h samples. The 24−48-h urine sample from each 
subject and a pool of the 0−168-h urine samples from 
subject  1  were  also  analysed  for  metabolite  profiling. 
Samples were mixed and centrifuged prior to the super-
natants being transferred to fresh tubes for metabolite 
profiling analysis.
Faecal  homogenates  for  metabolite  profiling  were 
pooled using an equal percentage by weight to generate 
two pools (0−48 h and 48−96 h) for each subject. An addi-
tional pool (0−168 h) was prepared using the samples col-
lected from subject 1. An aliquot (approximately 6 g) of 
each pool was extracted with three volumes of acetonitrile; 
samples were mixed and centrifuged. The supernatant 
was removed and the pellets were extracted twice with an 
additional 12 mL of acetonitrile each time. The combined 
supernatants were evaporated to dryness under a stream 
of nitrogen and the residue was re-suspended in a small 
volume (approximately 400 μL) of acetonitrile:1% formic 
acid in water (1:1). Samples were assayed for extraction 
recovery prior to metabolite profiling.
HPLC  analysis  for  metabolite  profiling  was  per-
formed using a Shimadzu LC-10ADVP (Shimadzu Corp., 
Columbia,  MD)  or  a  Waters  2695  Alliance  Separation 
Module (Waters Corp., Milford, MA) with the autosampler 
set to an ambient temperature of approximately 22°C.   
A SPD-10A VP UV-Vis Detector or a Waters 996 Photodiode 
array detector set to 254 nm was used to detect UV absor-
bance. [14C]Apremilast and metabolites were separated 
using a Phenomenex Luna C18(2) column (150 × 4.6 mm, 
3 μm; Phenomenex, Torrance, CA) equipped with a RP-18 
guard column (15 × 3.2 mm, 7 μm) or using an ACE 3 C18 
column (150 × 4.6 mm, 3 μm; Advanced Chromatography 
Technologies,  Aberdeen,  Scotland)  equipped  with  an 
ACE  3  guard  column  (10 × 3 mm,  3  μm).  The  mobile 
phases used were 0.4% formic acid in water; pH 3.2 with 
ammonium hydroxide (mobile phase A) and acetonitrile 
(mobile  phase  B).  The  column  temperature  was  30°C 
and the flow rate was 0.7 mL/min. The linear gradient 
was delivered as follows: 0−5 min to 100% A; 5−20 min 
to 85% A; 20−30 min hold at 85% A; 30−50 min to 65% A; 
50−60 min to 60% A; 60−70 min to 50% A; 70−75 min to 0% 
A; hold at 0% A until 80 min; return to initial conditions 
over 2 min.
Radioactivity profiles for excreta were determined by 
radiochromatography using liquid chromatography-ac-
curate radioisotope counting stop-flow system (LC-ARC; 
AIM Research Company, Wilmington, DE). Radioactivity 
was detected using a β-Ram Radioflow detector (IN/US 
Systems, Brandon, FL) equipped with a 1300-μL liquid 
cell. Liquid scintillation cocktail and column eluate were 
mixed at a ratio of 2.5:1. Radioactive peaks were quan-
tified  using  LC-ARC  data  handling  software.  Plasma 
radioactivity profiles were determined by collecting the 
column eluate into 96-well Deepwell LumaPlates at a rate 
of 0.25 min/fraction. The plates were dried and the radio-
activity  in  each  well  determined  using  a  PerkinElmer 
TopCount NXT Microplate Scintillation Counter. HPLC 
radiochromatograms were reconstructed using LC-ARC 
data handling software.
For some urine and faecal samples, extracts were pre-
pared by solid-phase extraction and repeatedly injected, 
and  fractions  were  collected  (0.25 min/well)  in  order 
to obtain sufficient metabolite concentrations to allow 
for additional mass spectrometry characterization. The 
M12  peak  isolated  from  urine  was  also  subjected  to 
β-glucuronidase hydrolysis to confirm its identity. A 2-mL 
solution of M12 in 0.2-M sodium phosphate buffer (pH 
6.7) was incubated with β-glucuronidase (360 units) at 
37°C for 4 h, and then extracted with ethyl acetate and 
analysed by LC/MS.
Metabolite characterization by mass spectrometry
Selected plasma, urine and faecal extracts, as well as iso-
lated metabolites were analysed by HPLC coupled with 
a radioactivity detector and mass spectrometer. For the 
mass spectrometry analysis, mobile phase B was changed 
to methanol, and for some samples, acetonitrile was added 
as a post-column addition at 0.2 mL/min. Minor changes 
to the LC gradient were also made for some samples to 
help  separate  radioactive  peaks  with  similar  retention 
times. Metabolites were characterized using a Finnigan 
LCQ  mass  spectrometer  (Thermo  Scientific,  Waltham, 1066  M. Hoffmann et al.
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MA) or a SCIEX Q Trap (Applied Biosystems, Foster City, 
CA), equipped with an electrospray source. The Finnigan 
mass spectrometer was operated in the positive ionization 
mode, while the SCIEX mass spectrometer was operated in 
the positive or negative ionization mode. The instrument 
settings and potentials were adjusted as necessary to pro-
vide optimal data. The Finnigan mass spectrometer was 
operated with an electrospray needle potential of 4.5 kV 
and a capillary temperature of 240°C. The collision-acti-
vated dissociation studies were conducted using helium 
as the collision gas. For the SCIEX mass spectrometer, the 
electrospray needle potential was 5.0 kV in the positive 
mode and 4.5 kV in the negative mode; the turbo probe 
temperature was 550°C, the curtain gas was nitrogen, the 
entrance potential was 10 V, the declustering potential was 
50 V and the collision energy was 8−25 eV.
PDE4 and TNF-α activity of apremilast metabolites
PDE4 enzyme was isolated from U937 human monocytic 
cells and used for testing inhibition in a cAMP hydrolysis 
assay as previously described (Schafer et al. 2010). For the 
TNF-α production assay, human peripheral blood mono-
nuclear cells (PBMC) were isolated from buffy coat of nor-
mal donor blood units (Blood Center of New Jersey, East 
Orange, NJ) by density centrifugation over Ficoll Hypaque 
(Pharmacia, Piscataway, NJ). Cells were cultured in RPMI 
1640  (Life  Technologies,  Grand  Island,  NY)  supple-
mented with 5% AB+ human serum (Gemini Bio-products, 
Woodland, CA), 2-mM L-glutamine, 100-U/mL penicillin 
and 100-μg/mL streptomycin (Life Technologies). PBMC 
(2 × 105  cells)  were  plated  in  96-well  flat-bottom  Costar 
tissue  culture  plates  (Corning,  NY)  in  duplicate.  Cells 
were  stimulated  with  lipopolysaccharides  (LPS)  (from 
Salmonella abortus equi; Sigma cat.no. L-1887, St.Louis, 
MO) at a final concentration of 1 ng/mL in the absence or 
presence of compounds. The compounds were dissolved 
in DMSO (Sigma) and subsequent dilutions were done in 
culture medium immediately before use. The compounds 
were added to cells 1 h before LPS stimulation. The cells 
were incubated for 16−18 h at 37°C in 5% CO2, and super-
natants were then collected, diluted with culture medium 
and assayed for TNF-α levels by enzyme-linked immuno-
sorbent assay (ThermoFisher, Rockford, IL). Fifty percent 
inhibitory concentrations (IC50) for the PDE4 enzymatic 
and TNF-α assay were calculated by non-linear regres-
sion  analysis  using  Prism  5.1  (GraphPad  Software). 
Regression curves were sigmoidal dose response curves 
with maximum and minimum constrained to 100% and 
0%, respectively.
Pharmacokinetic analysis
Pharmacokinetic data were generated by non-compart-
mental analysis of plasma or whole blood versus time 
profiles using WinNonlin (version 4.1, Enterprise Edition). 
For  individual  subjects,  the  peak  concentration  (Cmax), 
time to Cmax (Tmax), area under the concentration versus 
time curve from time zero to the last quantifiable concen-
tration (AUC0-t), area under the concentration versus time 
curve from time zero to infinity (AUC0−∞) and the appar-
ent terminal elimination half-life (t½) were determined. 
AUC0−t and AUC0−∞ were calculated using the linear trap-
ezoidal rule. AUC0−∞ was calculated as the sum of AUC0−t + 
Clast/λz, where Clast is the last observed quantifiable con-
centration.  The  terminal  elimination  rate  constant  (λz) 
and, therefore, t½ and AUC0−∞ were estimated by fitting a 
linear regression of log concentration against time values 
utilizing a minimum of three data points (excluding Cmax) 
that appeared to be on the terminal elimination portion 
of the concentration versus time curve. λz, t½ and AUC0−∞ 
were not estimated in cases where the terminal elimina-
tion phase did not exhibit a linear decline with a regres-
sion coefficient (r2) > 0.8, or the data points selected did 
not encompass a time interval of at least one t½.
Calculations
The amount of total radioactivity (ngEq) in urine and fae-
ces was determined by multiplying the volume or weight 
of the samples by the radioactivity concentration. The 
dose recovered at each time point was determined by 
total radioactivity in the sample, divided by the total dose 
administered, multiplied by 100%. For data values below 
the limit of quantification, a value of zero was assigned 
for calculations of means.
Results
Excretion of radioactivity
Following a single 20 mg, 100-μCi dose of [14C]apremilast, 
urine and faeces were collected from six subjects over 
216 h (9 days). Excretion of radioactivity was nearly com-
plete, with a mean recovery of approximately 97% (range 
94.1%−99.3%). The amount of radioactivity (expressed as 
percentage of dose) excreted in urine ranged from 47.4% 
to 71.2% (mean 57.9% ± 9.9%), whereas faecal excretion 
ranged from 27.6% to 50.8% (mean 39.2% ± 9.7%) over 
the collection period. The majority of the radioactivity 
(>90%) was recovered within the first 4 days (96 h) after 
dose administration (Figure 2).
Pharmacokinetic analysis
The  absorption  of  [14C]apremilast  was  relatively  rapid 
(Tmax  of  1.5 h)  and  the  plasma  half-life  was  moderate 
(approximately  7 h),  while  plasma  radioactivity  had  a 
much longer half-life (approximately 50 h) (Tables 1 and 2,   
Figure 3), suggesting the presence of metabolites that 
are  longer-lived  than  parent  compound.  Apremilast 
was generally not detected in plasma beyond the 48-h 
time point, whereas radioactivity was detected out to 
168 h following dose administration. Modest differences 
in  apremilast  AUC  determined  via  LC/MS  (1913 ± 339 
ng*h/mL)  or  via  radiochromatography  (2455 ± 690 
ngEq*h/mL) may be attributed to method and limit of 
detection differences. Based on radiochromatography, 
plasma exposure (AUC) of apremilast was approximately 
40% relative to total radioactivity. The pharmacokinetic 
parameters of some of the more abundant metabolites Disposition, metabolism and mass balance of apremilast  1067
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were  determined  using  radiochromatography  (Table 
2,  Figure  4).  The  peak  plasma  concentrations  of  the 
metabolites generally occurred later (Tmax of 1−5 h for 
metabolites vs. 1.5 h for apremilast) and the metabolites 
had somewhat longer t½ values than apremilast (11−16 h 
for metabolites vs 7 h for apremilast). The most abundant 
circulating metabolite was M12 (O-desmethyl apremi-
last glucuronide), which represented 39% of the circulat-
ing radioactivity and had an AUC similar to apremilast. 
In addition, nine other metabolites were detectable in 
plasma, none representing >7% of the circulating radio-
activity. The mean blood/plasma ratios of radioactivity 
were between 0.53 and 0.63 at all time points evaluated 
(data  not  shown),  indicating  no  noteworthy  binding 
of radioactivity (apremilast and its metabolites) to the 
blood cell constituents.
Metabolic profiles
HPLC radiochromatograms of plasma, urine and faecal 
homogenate from a representative subject are shown in 
Figure 2.  Cumulative elimination of radioactivity in urine and faeces after a single oral 20-mg dose of [14C]apremilast in male healthy 
subjects (● urine, ○ faeces, ■ total). Values are mean ± standard deviation.
Table 1.  Plasma and whole blood total radioactivity pharmacokinetic parameters following a single oral 20-mg dose of [14C]apremilast.
PK parameter Whole-blood total radioactivitya Plasma total radioactivitya Blood-to-plasma ratio
Cmax (ngEq/mL) 303 ± 77 527 ± 127 0.57
Tmax (h) 2.0 (1.0−3.0) 1.5 (1.0−3.0) NA
AUC0−t (ngEq*h/mL) 3489 ± 509 6201 ± 937 0.56
AUC0−∞ (ngEq*h/mL) 3664 ± 556 6632 ± 653 0.55
t½ (h) 16.3 ± 5.2 50.4 ± 8.7 NA
NA, not applicable; ngEq, ng [14C]apremilast equivalent.
aValues are reported as mean ± standard deviation except Tmax values, which are reported as median (min-max).
Table 2.  Mean ± standard deviation plasma pharmacokinetic parameters for apremilast and circulating metabolites after a single oral 
20-mg dose of [14C]apremilast.
  TRA Apremilasta Apremilastb M11 M12 M13 M14 M16
Cmax (ngEq/mL) 527 ± 127 333 ± 76 321 ± 134 20.2 ± 7.6 111 ± 36 7.5 ± 6.8 9.4 ± 4.3 27.6 ± 26.0
Tmax (h) 1.5 (1.0−3.0) 1.5 (1.0−3.0) 1.8 (1.0−2.5) 1.0 (0.5−2.5) 2.5 (1.0−2.5) 2.5 (1.0−24) 2.5 (1.0−24) 5.3 (1.0−8.0)
AUC0−t (ngEq*h/mL) 5483 ± 825c 1913 ± 339 2455 ± 690 139 ± 89 2124 ± 331 133 ± 125 269 ± 146 363 ± 54
AUC0−∞ (ngEq*h/mL) 6632 ± 653 1970 ± 343 2636 ± 705 232 ± 151 2446 ± 416 n/cd n/c 389 ± 91
t½ (h) 50.4 ± 8.7 6.8 ± 2.6 7.1 ± 2.7 10.7 ± 10.2 15.8 ± 3.9 n/c n/c 11.0 ± 2.4
Tmax, median and range; TRA, total radioactivity.
aApremilast concentrations in plasma determined using a Chiral LC/MS/MS assay.
bApremilast and metabolite concentrations in plasma calculated using plasma radioactivity concentrations and radiochromatography. 
cAUC0−48 was used for TRA for these calculations.
dNot calculated.1068  M. Hoffmann et al.
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Figure 5. Metabolite profiles were similar between sub-
jects  and  qualitatively  similar  at  different  time  points. 
Apremilast was the predominant radioactive component 
in plasma up to 8-h post-dose, after which M12 was the 
predominant compound. By 48-h post-dose, apremilast 
was not detected in plasma samples of most subjects. In 
plasma, apremilast plus metabolites M7, M11, M12, M13, 
M14 and M16 accounted for an average of 94.8% of the 
radioactivity in the samples.
Apremilast  was  a  minor  component  in  urine  col-
lected  up  to  48-h  post-dose,  representing  <3%  of  the 
dose (Table 3). The major urinary metabolite was M12, 
which accounted for 34% of the dose. An additional nine 
minor metabolites were observed in urine, each repre-
senting ≤4% of the dose. Apremilast was also a minor 
component  in  faeces  collected  up  to  96-h  post-dose, 
representing 4% of the dose. The two most abundant fae-
cal metabolites were the O-desmethyl metabolite (M3, 
5% of the dose) and its hydrolysis product (M9, 8% of the 
dose). The remaining 14 faecal metabolites each repre-
sented ≤3% of the dose. Approximately, 92.4% and 86.0% 
of  the  radioactivity  in  urine  and  faeces,  respectively, 
Figure 3.  Concentration versus time curves for radioactivity in plasma (○), apremilast in plasma (●) and radioactivity in blood (■) following 
a single oral 20-mg dose of [14C]apremilast in healthy male subjects. Values are mean ± standard deviation.
Figure 4.  Concentration versus time curves for total radioactivity (TRA), apremilast, M11, M12, M13, M14 and M16 in plasma following a 
single oral 20-mg dose of [14C]apremilast in healthy male subjects. Values are mean ± standard deviation.Disposition, metabolism and mass balance of apremilast  1069
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were characterized and identified as metabolites listed 
in Table 3.
Metabolite characterization
Figure 6 shows the proposed mass spectrometry frag-
mentation  pattern  for  apremilast,  Table  3  lists  the 
characteristic fragment ions for apremilast and the meta-
bolites,  and  Figure  7  shows  the  proposed  metabolite 
structures. Using reference standard, apremilast gener-
ated a protonated molecular ion, [M + H]+, at m/z 461. 
The product ions of m/z 461 mass spectrum included m/z 
257, 205, 178, 163 and 150. Loss of N-dioxoisoindlinyl 
Figure 5.  Representative radiochromatograms of (A) 0−24-h pooled plasma, (B) 0−24-h pooled urine and (C) 0−48-h pooled faeces after a 
single oral 20-mg dose of [14C]apremilast in healthy male subjects.1070  M. Hoffmann et al.
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acetamide generated m/z 257. Subsequent loss of hydro-
sulphonylmethane  generated  m/z  178  and  additional 
loss of ethane generated m/z 150. The N-dioxoisoindlinyl 
acetamide portion of the molecule generated the m/z 
205, and subsequent loss of C2H2O from the N-acetyl 
moiety generated m/z 163.
Metabolites M1/M2 generated a [M + H]+ at m/z 479, 
which was 18 Da larger than apremilast, consistent with 
hydrolysis products of apremilast. The product ion for 
M1/M2 at m/z 223 was 18 Da greater than apremilast, 
indicating the N-dioxoisoindlinyl acetamide portion of 
the molecule was the site of hydrolysis. Subsequent loss 
of NH3 yielded m/z 206, consistent with hydrolysis occur-
ring on the imide ring. Therefore, M1/M2 were identi-
fied as hydrolysis products of apremilast with hydrolysis 
occurring at either side of the nitrogen on the imide ring. 
The presence of M1/M2 in plasma was confirmed by LC/
MS/MS in the MRM mode.
The [M + H]+ for M3 was observed at m/z 447, which 
was  14 Da  lower  than  apremilast,  suggesting  loss  of  a 
methyl group. Product ions at m/z 243, 164 and 136 were 
also  14 Da  lower  than  those  observed  for  apremilast, 
Figure 6.  Mass spectral fragmentation of apremilast.
Table 3.  Fragment ions and relative amounts for apremilast metabolites characterized in plasma, urine and faeces.
Metabolite Characterization Plasma (% AUC  
relative to TRA)d
% of dose excreted
Number Pathway [M + H]+ a Fragment Ions Urine Faeces
Apremilast Unchanged 461 257, 205, 178, 163, 150 44.8 2.8 4.1
M1/M2 Hydrolysis products of apremilast 479 274, 257, 223, 206, 178 D 0.9 0.5
M3 O-Demethylation 447 243, 164, 136 D D 4.6
M4 O-Demethylation, N-deacetylation 405 243, 164 ND ND 2.4
M7 N-Deacetylation 419 257, 178, 163 D D 0.1
M8 Hydroxylation, O-demethylation, 
N-deacetylation
421 243, 179, 164 ND ND 1.0
M9 Hydrolysis product of M3 465 260, 243, 223, 206, 164 ND ND 7.7
M10 Hydroxylation, O-demethylation 463 243, 221, 164, 163, 136 ND ND 1.3
M11 Hydroxylation, N-deacetylation 435 257, 179, 178 2.5 ND 1.4
M12 O-Demethylation, glucuronidation 623 447, 243 38.7 33.7 ND
M13 O-Deethylation, glucuronidation 609 488, 433, 229, 205, 150 2.4 2.0 ND
M14 O-Demethylation, N-deacetylation, 
glucuronidation
581 405, 243 4.9 4.0 ND
M15 Hydrolysis product of M12 641 465, 436, 260, 243, 164 ND 3.3 ND
M16 Hydroxylation, glucuronidation 653 477, 397, 257 6.6 0.6 ND
M17 Hydroxylation 477 257, 221, 178, 163 D 1.2 0.9
M18 Hydrolysis 222c 178, 136, 134, 92 ND ND 1.4
M19 O-Demethylation, O-deethylation 419 215, 205, 163, 136 ND ND 0.8
M20b O-Demethylation, O-deethylation, 
N-deacetylation
377 215, 163, 136 ND ND 0.5
M21b Hydroxylation, O-demethylation, 
O-deethylation
435 221, 215, 163, 136 ND ND
M22 Hydrolysis, O-deethylation 451 246, 229, 223, 206, 150, 135 ND ND 0.6
M23 Hydrolysis, hydroxylation 238c 194, 150, 136, 92, 74 ND ND 3.0
ND, not detected; D, detected by MS, but at concentrations too low to accurately quantify by radiochromatography.
aMany compounds were observed as [M + H]+ and [M + NH4]+.
bM20 and M21 coeluted under the HPLC conditions used.
cCharacterized in negative mode, so values are [M − H]−.
dAUC0−t (unchanged drug or metabolite)/AUC0−48 (TRA) * 100%.Disposition, metabolism and mass balance of apremilast  1071
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consistent  with  the  O-demethylation  of  the  methoxy 
group of the phenyl ring. Using M3 from mouse faeces, 
the MS/MS spectra for M3 was shown to be consistent 
with  CC-15604  reference  standard  and,  therefore,  M3 
was identified as O-desmethyl apremilast. The presence 
of M3 in plasma and urine was confirmed by LC/MS/MS 
in the MRM mode.
The [M + H]+ for M4 was observed at m/z 405, which 
was 56 Da lower than apremilast. Product ions at m/z 243 
and 164 were 14 Da lower than the corresponding ions 
Figure 7.  Metabolic scheme of apremilast in humans. For hydrolysed phthalidomide ring products, only one of two possible forms is shown. [M5, 
O−desethyl apremilast, was not observed in this study and is a proposed intermediate metabolite] (GLU: glucuronic acid, * site of 14C label).1072  M. Hoffmann et al.
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observed for apremilast, suggesting O-demethylation of 
the methoxy group of the phenyl ring. The [M + H]+ for 
M4 at m/z 405 is 42 Da lower than M3, consistent with 
N-deacetylation of O-desmethyl apremilast. Metabolite 
M4  was  identified  as  N-deacetylated,  O-desmethyl 
apremilast.
The  [M  +  H]+  for  M7  was  observed  at  m/z  419, 
which  is  42 Da  lower  than  apremilast,  consistent  with 
N-deacetylation. The product ions at m/z 257, 178 and 
163, as well as the retention time of 63.3 min were consis-
tent with those observed for N-deacetylated apremilast 
reference  standard.  Using  M7  from  mouse  faeces,  the 
MS/MS spectra for M7 was shown to be consistent with 
CC-10055  reference  standard  and,  therefore,  M7  was 
identified as N-deacetylated apremilast.
Metabolite M8 had a [M + H]+ at m/z 421, which was 
40 Da lower than apremilast. Product ions m/z 243 and 
164  for  M8  were  14 Da  lower  than  the  corresponding 
product ions for apremilast, suggesting O-demethylation 
of the methoxy group on the phenyl ring. The product ion 
m/z 179 for M8 was 26 Da lower than the corresponding 
product ion for apremilast, suggesting hydroxylation and 
N-deacetylation  on  the  N-dioxoisoindlinyl  acetamide 
portion of the molecule. Metabolite M8 was identified as 
hydroxylated N-deacetylated, O-desmethyl apremilast.
The [M + H]+ for M9 was observed at m/z 465, which 
is 4 Da larger than apremilast. The product ions at m/z 
243 and 164 were 14 Da lower than the corresponding 
ions for apremilast, consistent with O-demethylation of 
the methoxy group on the phenyl ring. The product ion 
for  M9  at  m/z  223  was  18 Da  greater  than  apremilast, 
suggesting  hydrolysis  on  the  N-dioxoisoindlinyl  acet-
amide portion of the molecule. Subsequent loss of NH3 
yielded m/z 206, consistent with hydrolysis occurring on 
the imide ring. Similar product ions were observed for 
metabolites M1/M2 (hydrolysis products of apremilast). 
Metabolite M9 was characterized as the hydrolysis prod-
uct of O-desmethyl apremilast.
Metabolite M10 had a [M + H]+ at m/z 463, which was 
2 Da greater than apremilast. Product ions m/z 243, 164 
and 136 for M10 were 14 Da lower than the corresponding 
product ions for apremilast, suggesting O-demethylation 
of the methoxy group on the phenyl ring. The product ion 
m/z 221 for M10 was 16 Da greater than the correspond-
ing  product  ion  for  apremilast,  suggesting  hydroxyla-
tion on the N-dioxoisoindlinyl acetamide portion of the 
molecule. The product ion for M10 at m/z 163 was also 
observed for apremilast, suggesting the isoindoline-dione 
portion of the molecule was not the site of hydroxylation. 
Therefore, M10 was identified as acetamide hydroxylated, 
O-desmethyl apremilast.
The [M + NH4]+ for M11 was observed at m/z 452, cor-
responding to a molecular weight of 434, which is 26 Da 
less than apremilast. The product ions at m/z 257 and 
178  were  also  observed  for  apremilast,  indicating  the 
N-dioxoisoindlinyl  acetamide  portion  of  the  molecule 
was the site of metabolism. The product ion for M11 at 
m/z 179, suggested hydroxylation and N-deacetylation 
on  the  N-dioxoisoindlinyl  acetamide  portion  of  the 
molecule. Metabolite M11 was characterized as hydroxy-
lated N-deacetylated apremilast. The presence of M11 
in  plasma  was  confirmed  by  LC/MS/MS  in  the  MRM 
mode.
The [M + NH4]+ for M12 was observed at m/z 640, cor-
responding to a molecular weight of 622, which is 162 Da 
greater than apremilast. Loss of 176 Da led to the product 
ion at m/z 447 for M12, indicating M12 was a glucuronic 
acid conjugate. The product ions at m/z 447 and 243 for 
M12 were consistent with O-demethylation of apremi-
last. Additionally, isolation of the M12 radioactive peak   
followed  hydrolysis  by  β-glucuronidase  resulted  in  a 
single major radioactive product, which was identified by 
LC/MS to be metabolite M3. Therefore, M12 was identi-
fied as the glucuronide conjugate of O-desmethyl apre-
milast. The presence of M12 in plasma was confirmed 
by LC/MS/MS in the MRM mode.
The [M + H]+ for M13 was observed at m/z 609, which 
is 148 Da greater than apremilast. Loss of 176 Da led to 
the product ion at m/z 433 for M13, indicating M13 was 
a glucuronic acid conjugate. The product ion at m/z 229 
was 28 Da lower than the corresponding product ion for 
apremilast and was consistent with O-deethylation of the 
ethoxy group of the phenyl ring. M13 was identified as 
the glucuronide conjugate of O-desethyl apremilast. The 
presence of M13 in plasma was confirmed by LC/MS/MS 
in the MRM mode.
The [M + NH4]+ for M14 was observed at m/z 598, cor-
responding to a molecular weight of 580, which is 120 Da 
greater than apremilast. The product ion at m/z 405 for 
M14  was  consistent  with  the  loss  of  176 Da  from  the 
metabolite, indicating M14 was a glucuronic acid conju-
gate. The product ions at m/z 405 and 243 for M14 were 
consistent  with  N-deacetylation  and  O-demethylation 
of apremilast. Therefore, M14 was characterized as the 
glucuronide conjugate of N-deacetylated, O-desmethyl 
apremilast.  The  presence  of  M14  in  plasma  was  con-
firmed by LC/MS/MS in the MRM mode.
The [M + H]+ for M15 was observed at m/z 641, which 
is 180 Da larger than apremilast. The product ion at m/z 
465 indicated the loss of 176 Da, suggesting M15 was a 
glucuronic acid conjugate. Further fragmentation of the 
product ion at m/z 465 yielded product ions similar to 
those observed for metabolite M9 (the hydrolysis prod-
uct  of  O-desmethyl  apremilast).  Metabolite  M15  was, 
therefore, characterized as the hydrolysis product of the 
glucuronide conjugate of O-desmethyl apremilast.
The molecular weight of M16 was determined to be 
652 based on the [M + NH4]+ at m/z 670. This molecu-
lar weight was 192 Da larger than apremilast, indicative 
of  hydroxylation  plus  glucuronidation.  The  product 
ion at m/z 397 was consistent with hydroxylation and 
glucuronidation  on  the  N-dioxoisoindlinyl  acetamide 
portion of the molecule. Additionally, the product ion at 
m/z 257 was also observed for apremilast indicating the 
N-dioxoisoindlinyl  acetamide  portion  of  the  molecule 
was the likely site of metabolism. Therefore, M16 was Disposition, metabolism and mass balance of apremilast  1073
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characterized as the glucuronide conjugate of hydroxy-
lated  apremilast,  with  the  site  of  metabolism  on  the 
N-phenylacetamide  portion  of  the  N-dioxoisoindlinyl 
acetamide ring. Using M16 from mouse plasma and bile, 
the MS/MS spectra for M16 was shown to be consistent 
with CC-16557 reference standard and, therefore, M16 
was  identified  as  acetamide  hydroxylation  apremilast 
glucuronide. The presence of M16 in plasma was con-
firmed by LC/MS/MS in the MRM mode.
The [M + H]+ for M17 was observed at m/z 477, which 
is 16 Da larger than apremilast suggesting a hydroxylated 
metabolite. The product ion at m/z 221 was 16 Da greater 
than the corresponding product ion for apremilast, sug-
gesting the N-dioxoisoindlinyl acetamide portion of the 
molecule was the likely site of metabolism. The product 
ion at m/z 163 was also observed for apremilast indicating 
that the acetamide was the site of hydroxylation. Using 
M17 from mouse plasma and bile, the MS/MS spectra for 
M17 was shown to be consistent with CC-16401 reference 
standard and, therefore, M17 was identified as hydroxy 
apremilast, with the acetamide being the site of metabo-
lism. The presence of M17 in plasma was confirmed by 
LC/MS/MS in the MRM mode.
The [M + H]− for M18 was observed at m/z 222, suggest-
ing cleavage of apremilast, with a significant portion of 
the molecule lost. Based on the molecular weight and the 
known metabolic pathways for apremilast, the structure 
of M18 was suggested to be 3-acetamide-phthalic acid. 
Product ions at m/z 178, 136, 134 and 92 were consistent 
with this structure. Therefore, M18 was characterized as 
3-acetamide-phthalic acid.
The [M + H]+ for M19 was observed at m/z 419, cor-
responding to a molecular weight of 418, which is 42 Da 
less than apremilast. The product ions at m/z 205 and 
163  were  also  observed  for  apremilast,  indicating  the 
N-dioxoisoindlinyl  acetamide  portion  of  the  molecule 
was not the site of metabolism. The product ions for M19 
at m/z 215 and 136 were 42 Da less than the correspond-
ing product ions of apremilast, suggesting O-deethylation 
and O-demethylation of the ethoxy and methoxy groups 
of the phenyl ring. Metabolite M19 was characterized as 
O-desmethyl, O-desethyl apremilast.
The [M + H]+ for M20 was observed at m/z 377, which 
is 84 Da less than apremilast. The product ions at m/z 
215  and  136  were  42 Da  less  than  the  corresponding 
product  ions  of  apremilast,  suggesting  O-deethylation 
and O-demethylation of the ethoxy and methoxy groups 
of the phenyl ring. The product ion for M20 at m/z 163 
was  consistent  with  N-deacetylation.  Therefore,  M20 
was  characterized  as  N-deacetylated,  O-desmethyl, 
O-desethyl apremilast.
The [M + NH4]+ for M21 was observed at m/z 452, cor-
responding to a molecular weight of 434, which is 26 Da 
greater  than  apremilast.  The  product  ions  at  m/z  215 
and 136, were 42 Da less than the corresponding prod-
uct  ions  of  apremilast,  suggesting  O-deethylation  and 
O-demethylation of the ethoxy and methoxy groups of the 
phenyl ring. The product ion at m/z 221 was 16 Da greater 
than the corresponding product ion for apremilast, sug-
gesting the N-dioxoisoindlinyl acetamide portion of the 
molecule was the likely site of hydroxylation. The product 
ion at m/z 163 was also observed for apremilast indicat-
ing  that  the  acetamide  was  the  site  of  hydroxylation. 
Metabolite M21 was, therefore, characterized as hydroxy 
O-desmethyl O-desethyl apremilast, with the acetamide 
being the site of hydroxylation.
The [M + H]+ for M22 was observed at m/z 451, which 
is 10 Da less than apremilast. The product ion at m/z 229 
was 28 Da lower than the corresponding ions for apremi-
last, consistent with O-deethylation of the ethoxy group 
on the phenyl ring. The product ion for M22 at m/z 223 
was 18 Da greater than apremilast, suggesting hydrolysis 
on the N-dioxoisoindlinyl acetamide portion of the mol-
ecule. Subsequent loss of NH3 yielded m/z 206, consis-
tent with hydrolysis occurring on the imide ring. Similar 
product  ions  were  observed  for  metabolites  M1/M2 
(hydrolysis products of apremilast). Metabolite M22 was 
characterized  as  the  hydrolysis  product  of  O-desethyl 
apremilast.
The [M + H]− for M23 was observed at m/z 238, which 
was  16 Da  larger  than  metabolite  M18.  Based  on  the 
molecular  weight  and  the  known  metabolic  pathways 
for apremilast, the structure of M18 was suggested to be 
hydroxy 3-acetamide-phthalic acid. Product ions at m/z 
194, 150, 136 and 92 were consistent with this structure, 
with hydroxylation occurring on the acetamide portion 
of  the  molecule.  Therefore,  M23  was  characterized  as 
hydroxy 3-acetamide-phthalic acid.
PDE4 and TNF-α activity of apremilast metabolites
The major apremilast metabolites were at least 50-fold 
less active than apremilast with regard to their ability to 
inhibit PDE4 and TNF-α (Table 4). The minor metabo-
lites  M7  and  M17  did  retain  some  PDE4  and  TNF-α 
inhibition activity, with IC50 values similar to those of 
apremilast.
Table 4.  Phosphodiesterase type 4 and tumour necrosis factor-α 
inhibitory activities of apremilast and its metabolites.
Compound PDE4 IC50 (μM) TNF-α IC50 (μM)
Apremilast (S-isomer) 0.074 0.077
M1/M2; Hydrolysis products  
of apremilast (S-isomer)
120 77
M3; O-Desmethyl apremilast 
(S-isomer)
8.3 5.6
M5; O-desethyl apremilast 
(racemate)
44 4.9
M7; N-deacetyl metabolite 
(S-isomer)
0.16 0.13
M12; O-Desmethyl apremilast 
glucuronide (S-isomer)
>100 >10
M14; O-Desmethyl, N-deacetyl 
apremilast glucuronide
>80 >10
M16; Acetamide hydroxylation 
glucuronide (S-isomer)
6.5 >10
M17; Acetamide hydroxylation 
(S-isomer)
0.094 0.0211074  M. Hoffmann et al.
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Discussion
Pharmacokinetic  analysis  of  total  radioactivity  and 
apremilast following a single oral [14C]apremilast dose 
to  healthy  volunteers  suggests  rapid  absorption,  with 
plasma  Tmax  values  ≤2 h.  Additionally,  the  amount  of 
unchanged apremilast in faeces (4% of the dose), sug-
gests absorption of the majority of the apremilast dose in 
humans. Elimination of radioactivity from blood, as well 
as apremilast and its major metabolites from plasma, was 
moderate with half-lives ranging between 7 and 16 h with 
some metabolites having slightly longer half-lives than 
apremilast.  The  one  exception  being  metabolite  M14, 
which had concentrations that were similar in all of the 
plasma  samples  analysed  between  8  and  48 h  and  for 
which a half-life was not calculated. The terminal elimi-
nation  half-life  of  total  radioactivity  from  plasma  was 
significantly longer (approximately 50 h) mostly because 
the lower detection limit in plasma allowed for radioac-
tivity to be detected out to 168 h, as compared with 48 and 
72 h for apremilast in plasma and radioactivity in blood, 
respectively. The long half-life of radioactivity in plasma 
would likely result in little accumulation because it is 
based on the concentrations observed in the 96−168-h 
samples,  which  were  generally  100-fold  less  than  the 
Cmax values. As a result, approximately 90% of the AUC0−∞ 
for radioactivity in plasma was between 0 and 96 h, with   
the remaining (AUC96−∞) accounting for only 10%. This is 
consistent with the excretion data that showed recovery 
of  radioactivity  was  fairly  rapidly  (>92%  radioactivity 
recovered at 96 h) and nearly complete by 216 h (>97%).
The pharmacokinetic parameters reported for apre-
milast in this study are comparable to previously pub-
lished data in patients with severe plaque-like psoriasis 
(Gottlieb  et  al.  2008).  In  that  study,  patients  received 
20 mg of apremilast daily for 29 days, with pharmacoki-
netic  samples  collected  following  the  final  dose.  Even 
though samples were collected following multiple daily 
doses, the Tmax (2 h), Cmax (207 ng/mL) and AUC0−24 (1799 
ng*h/mL) values reported were similar to those reported 
in this study suggesting little accumulation of the drug. 
The difference in Cmax values between the studies is likely 
due to the different dosage forms used in the studies, oral 
suspension in this study and capsules in the multiple 
dose study.
Apremilast was extensively metabolized in humans, 
with approximately 7% of the dose excreted unchanged 
and 45% of the circulating radioactivity identified as apre-
milast  (based  on  radiochromatography)  through  48 h. 
The  predominant  circulating  and  excreted  metabolite 
was M12 (O-desmethyl apremilast glucuronide), which 
accounted for 39% of the circulating radioactivity and 
34% of the excreted dose. The other circulating metabo-
lites were formed via a number of pathways, including 
O-demethylation,  O-deethylation,  N-deacetylation, 
hydrolysis, hydroxylation and/or glucuronidation. Since 
the O-demethylation of apremilast is primarily catalysed 
by CYP3A4 (data not shown), the effects of ketoconazole 
(a known CYP3A4 inhibitor) co-administration on the 
pharmacokinetics of apremilast have been evaluated in 
healthy subjects (Wu et al. 2006). Co-administration of 
ketoconazole resulted in small but consistent increases 
in the mean apremilast Cmax (5% increase) and AUC (36% 
increase).
Based on urinary radioactivity, at least 58% of the drug 
was absorbed, and if faecal metabolites are included in 
the calculation, the amount absorbed may be >80%. The 
urinary metabolites of apremilast were similar to those 
observed  in  plasma,  while  the  metabolites  in  faeces 
were primarily the aglycone and/or hydrolysis products 
of  the  metabolites  observed  in  circulation,  suggesting 
they were initially formed in the liver, excreted into bile 
and subsequently cleaved or hydrolysed in the intestine. 
Hydrolysis of apremilast, and presumably its metabolites, 
occurs non-enzymatically in solution at neutral pH and 
possibly enzymatically in plasma and hepatocytes (data 
not shown). Together with the ketoconazole interaction 
data, these data suggest that multiple pathways, including 
CYP3A4-mediated metabolism, non-enzymatic hydroly-
sis, non-CYP3A4-mediated metabolism and elimination 
of unchanged drug, play important roles in the clearance 
of apremilast.
Most of the circulating apremilast metabolites were 
tested  for  their  PDE4  and  TNF-α  inhibitory  activities 
and the major metabolites were substantially (>50-fold) 
less active than apremilast. The minor metabolites M7 
and M17 did retain some pharmacological activity but 
were present in circulation at concentrations that were 
generally <2% relative to apremilast and, therefore, are 
unlikely  to  contribute  to  the  pharmacological  activity 
of apremilast. These data are consistent with work that 
has  been  performed  evaluating  the  structure-activity 
relationship of PDE4 inhibitors (Man et al. 2009; Van der 
Mey et al. 2001; Kodimuthali et al. 2008). Based on these 
data, substitutions larger than a methoxy or ethoxy group 
at the 4-position of the phenyl ring lead to a significant 
reduction  in  PDE4  inhibition.  Likewise,  hydrolysis  of 
the phthalimide ring, as in M1/M2 has been shown to 
decrease TNF-α inhibition (McHugh & Rowland, 1997), 
and presumably PDE4 inhibition as well.
In  summary,  this  study  demonstrated  that  apremi-
last was rapidly absorbed following oral dosing and the 
majority of the radioactivity was eliminated within 96 h. 
While the predominant clearance pathway for apremilast 
was  CYP-mediated  metabolism,  additional  clearance 
pathways  also  contributed.  Although  apremilast  was 
one of the major components in plasma, absorbed drug 
was also extensively metabolized via multiple pathways 
(O-demethylation,  O-deethylation,  N-deacetylation, 
hydroxylation, glucuronidation and/or hydrolysis), with 
the  predominant  circulating  and  excreted  metabolite 
formed via O-demethylation followed by glucuronida-
tion. Based on the PDE4 and TNF-α inhibitory effects 
of the metabolites, it is unlikely that metabolites con-
tribute  appreciably  to  the  pharmacological  activity  of 
apremilast.Disposition, metabolism and mass balance of apremilast  1075
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